Loss of PTEN Expression as a Prognostic Marker for Tongue Cancer

Lee, Janet I.; Soria, Jean Charles; Hassan, Khaled A.; El‐Naggar, Adel K.; Tang, Ximing; Liu, Diane D.; Hong, Waun Ki; Li, Mao

doi:10.1001/archotol.127.12.1441

Cited by 118 publications

(116 citation statements)

References 16 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…26 Other authors have reported that loss of PTEN protein expression is not uncommon and has been shown to be an independent predictive factor of poor outcome in tongue cancers. 27 Regarding allelic losses affecting PTEN gene, our results are in agreement with those reported by others on HNSCC cell lines and primary tumors. 28 No significant differences in the rate of 10q23 LOH were found with respect to any clinicopathological feature, which differs from the specific association between loss of genetic material on 10q and nodal metastasis reported in a CGH study on HNSCC.…”

Section: Discussionsupporting

confidence: 92%

Retracted: Frequent genetic and biochemical alterations of the PI 3‐K/AKT/PTEN pathway in head and neck squamous cell carcinoma

Pedrero

Carracedo

Pinto

et al. 2004

Intl Journal of Cancer

238

163

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Retracted: Frequent genetic and biochemical alterations of the PI 3‐K/AKT/PTEN pathway in head and neck squamous cell carcinoma

Pedrero

Carracedo

Pinto

et al. 2004

Intl Journal of Cancer

238

163

View full text Add to dashboard Cite

“…Previously unknown somatic mutations in 79 primary squamous cell carcinomas include recurrent E322K substitutions in the MAPK1 gene (8%), inactivating mutations in the HLA-B gene (9%), and mutations in EP300 (16%), FBXW7 (15%), NFE2L2 (4%), P53 (5%) and ERBB2 (6%). The association of poor prognosis with PTEN aberration has also been reported previously in glioma 41 and tongue carcinoma 42 . Whether PTEN methylation contributes to the development of cervical cancer and affects the prognosis has not been elucidated.…”

Section: Referencessupporting

confidence: 72%

PTEN expression in patients with carcinoma of the cervix and its association with p53, Ki-67 and CD31

Loures¹,

Cândido²,

Vidigal³

et al. 2014

Rev. Bras. Ginecol. Obstet.

View full text Add to dashboard Cite

PURPOSE: To investigate protein expression and mutations in phosphatase and tensin homolog (PTEN) in patients with stage IB cervical squamous cell carcinoma (CSCC) and the association with clinical-pathologic features, tumor p53 expression, cell proliferation and angiogenesis. METHODS: Women with stage IB CSCC (n=20 -Study Group) and uterine myoma (n=20 -Control Group), aged 49.1±1.7 years (mean±standard deviation, range 27-78 years), were prospectively evaluated. Patients with cervical cancer were submitted to Piver-Rutledge class III radical hysterectomy and pelvic lymphadenectomy and patients in the Control Group underwent vaginal hysterectomy. Tissue samples from the procedures were stained with hematoxylin and eosin for histological evaluation. Protein expression was detected by immunohistochemistry. Staining for PTEN, p53, Ki-67 and CD31 was evaluated. The intensity of PTEN immunostaining was estimated by computer-assisted image analysis, based on previously reported protocols. Data were analyzed using the Student's t-test to evaluate significant differences between the groups. Level of significance was set at p<0.05. RESULTS: The PTEN expression intensity was lower in the CSCC group than in the Control (benign cervix) samples (150.5±5.2 versus 204.2±2.6; p<0.001). Our study did not identify any mutations after sequencing all nine PTEN exons. PTEN expression was not associated with tumor expression of p53 (p=0.9), CD31 (p=0.8) or Ki-67 (p=0.3) or clinical-pathologic features in patients with invasive carcinoma of the cervix. CONCLUSIONS: Our findings demonstrate that the PTEN protein expression is significantly diminished in CSCC.

show abstract

“…29,30 These reports, however, did not elucidate whether or not the increased activity of AKT could be directly related to the resistance to chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer

Oki

Baba

Tokunaga

et al. 2005

Intl Journal of Cancer

168

130

View full text Add to dashboard Cite

Growth factor receptor-mediated signal transduction has been implicated in conferring resistance to conventional chemotherapy on cancer cells. We describe a pathway that involves AKT/PI3K to mediate chemoresistance in gastric cancer patients. Primary gastric carcinoma tissues and corresponding normal mucosa were obtained from 76 gastric cancer patients who underwent surgery in the Department of Surgery II in Kyushu University Hospital from the years 1996-2000. AKT activation was investigated by immunostaining with a phosphorylation-specific antibody, and LOH (loss of heterozygosity) of PTEN was studied in the same samples. AKT was phosphorylated in 22 cases (28.9%) of gastric cancer cases. AKT and phosphorylated AKT were not correlated with any clinicopathological factor. We found that the gastric cancer patients who had higher AKT phosphorylation (activated AKT) seemed to have LOH of PTEN (p 5 0.0008). When the chemotherapeutic sensibilities of these patients were studied in an MTT assay, it was found that the activated AKT was associated with increased resistance to multiple chemotherapeutic agents (5-fluorouracil, adriamycin, mitomycin C and cis-platinum). The results of our study indicate that AKT activation and LOH of PTEN plays an important role in conferring a broad-spectrum chemoresistance in gastric cancer patients. It also indicates that AKT may therefore be a novel molecular target for therapies or chemosensitivity tests that improve the outcomes of gastric cancer patients. ' 2005 Wiley-Liss, Inc.

show abstract

Loss of PTEN Expression as a Prognostic Marker for Tongue Cancer

Cited by 118 publications

References 16 publications

Retracted: Frequent genetic and biochemical alterations of the PI 3‐K/AKT/PTEN pathway in head and neck squamous cell carcinoma

Retracted: Frequent genetic and biochemical alterations of the PI 3‐K/AKT/PTEN pathway in head and neck squamous cell carcinoma

PTEN expression in patients with carcinoma of the cervix and its association with p53, Ki-67 and CD31

Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer

Contact Info

Product

Resources

About